Table 3.
Comparison between survivor and non-survivor ICU-AAV patients and univariate logistic regression analysis for ICU mortality
| Survivors (n = 82) | Non-survivors (n = 15) | p value | Univariate logistic regression | |||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | ||||
| Baseline characteristics | ||||||
| Gender (female), n (%) | 41 (50) | 4 (26.7) | 0.158 | 0.36 | 0.11–1.24 | 0.105 |
| Age (years), median [IQR] | 61.0 [47.0–70.3] | 67.0 [65.0–75.0] | 0.212 | 0.98 | 0.94–1.02 | 0.311 |
| Hypertension, n (%) | 32 (39.0) | 3 (20.0) | 0.158 | 0.39 | 0.10–1.49 | 0.169 |
| ANCA | ||||||
| c-ANCA type, n (%) | 54 (65.9) | 7 (46.7) | 0.157 | 0.45 | 0.15–1.38 | 0.164 |
| AAV relapse, n (%) | 19 (23.2) | 1 (6.7) | 0.185 | 0.24 | 0.03–1.92 | 0.177 |
| AAV involvement | ||||||
| Heart, n (%) | 14 (17.1) | 3 (20.0) | 0.723 | 1.21 | 0.30–4.87 | 0.784 |
| CNS, n (%) | 5 (6.1) | 3 (20.0) | 0.104 | 3.85 | 0.81–18.2 | 0.089 |
| Digestive, n (%) | 7 (8.5) | 2 (13.3) | 0.626 | 1.64 | 0.31–8.83 | 0.559 |
| ENT, n (%) | 33 (40.2) | 3 (21.4) | 0.159 | 0.37 | 0.10–1.41 | 0.147 |
| Kidney | ||||||
| Serum creatinine (µmol/L), median [IQR] | 364.0 [117.5–503.0] | 229.0 [104.0–682.0] | 0.824 | 1.00 | 0.99–1.00 | 0.878 |
| AKIN > 1, n (%) | 74 (90.2) | 15 (100) | 0.351 | 1.51 | 0.17–13.1 | 0.706 |
| RRT, n (%) | 43 (52.4) | 12 (80.0) | 0.086 | 3.53 | 0.93–13.5 | 0.064 |
| Lung, n (%) | 71 (86.6) | 14 (93.3) | 0.685 | 2.17 | 0.26–18.2 | 0.475 |
| DAH, n (%) | 51 (62.2) | 11 (73.3) | 0.562 | 1.67 | 0.49–5.71 | 0.412 |
| Respiratory assistance, n (%) | 52 (63.4) | 14 (93.3) | 0.032 | 8.51 | 1.07–67.9 | 0.043 |
| Infectious event, n (%) | 26 (31.7) | 13 (86.7) | <0.001 | 14.0 | 2.94–66.6 | 0.001 |
| Vasopressors, n (%) | 17 (20.7) | 9 (60.0) | 0.002 | 5.73 | 1.79–18.4 | 0.003 |
| Plasma exchange*, n (%) | 39 (47.6) | 7 (46.7) | 0.949 | 0.96 | 0.32–2.91 | 0.949 |
| Cyclophosphamide*, n (%) | 52 (63.4) | 14 (93.3) | 0.032 | 8.51 | 1.07–67.9 | 0.043 |
| SAPS II, median [IQR] | 37.5 [28.8–49.3] | 52.0 [33.0–66.0] | 0.006 | 1.06 | 1.02–1.10 | 0.003 |
| SOFA, median [IQR] | 6.0 [4.0–9.0] | 8.0 [6.0–13.0] | 0.040 | 1.21 | 1.04–1.41 | 0.013 |
| BVAS, median [IQR] | 23.0 [18.0–28.0] | 21.0 [20.0–27.0] | 0.916 | 1.01 | 0.94–1.08 | 0.899 |
OR odd ratio, CI confidence interval, ANCA anti-neutrophil cytoplasmic antibodies, c-ANCA cytoplasmic ANCA, AAV ANCA-associated vasculitis, CNS central nervous system, ENT ear nose throat, AKIN acute kidney injury network score, RRT renal replacement therapy, DAH diffuse alveolar hemorrhage
* Started before or during the ICU stay